AMNEAL PHARMACEUTICALS INC CLASS A (AMRX)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for AMRX
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| AMRX | Chief Policy Officer; Director | 59 | ["General Management", "Biosciences, Pharmaceuticals", "Regulatory", "Compliance", "Legal"] | [] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| HIMS | Chief Policy Officer and Director | 59 | ["C-Suite/Strategic Leadership Experience","Healthcare Industry","Medical and/or Scientific Expertise","Legal, Regulatory, and/or Public Policy Expertise","Public Company Board Experience","International Experience","Chief Executive Officer of strategic regulatory consulting firms","Global Head of Regulatory Excellence at AstraZeneca","Head of Strategic Global Quality and Regulatory Policy at Mylan N.V.","Senior leader at the FDA including Deputy Commissioner for Global Regulatory Operations and Policy","Director of the Office of Compliance of the Center for Drug Evaluation and Research","Trial Attorney in the Office of Consumer Litigation of the U.S. Department of Justice"] | ["Risk Committee"] | 2026 |
Biography sourced from the proxy statement filing.
Deb Autor is Chief Policy Officer and a member of the Board of Hims & Hers Health and Chair of the Board of the FDA Alumni Association. She is also CEO of Autor Strategies, LLC, a strategic regulatory consulting firm. She previously served as CEO of Healthcare Innovation Catalysts, a provider of regulatory affairs, clinical advisory, quality, compliance, federal partnership, and strategic advisory services to global life sciences organizations. Ms. Autor has also served as a Scientific Advisory Council Member of the Centre for Innovation in Regulatory Science and as a Board Member of Pardes Biosciences, the Antimicrobial Resistance Industry Alliance, the United States Pharmacopoeia Quality Institute, and the Parenteral Drug Association. From 2019-2021, Ms. Autor was Global Head of Regulatory Excellence at AstraZeneca, where she led multiple regulatory functions for all AstraZeneca products globally. Before joining AstraZeneca, Ms. Autor served at Mylan N.V. from 2013-2019, where she was Head of Strategic Global Quality and Regulatory Policy and Head of Global Quality. Ms. Autor was a senior leader at FDA from 2001-2013, most recently as Deputy Commissioner for Global Regulatory Operations and Policy where she oversaw all FDA inspections, criminal investigations and international operations for human and veterinary drugs, biologics, medical devices, tobacco and food. Before that, Ms. Autor served as Director of the Office of Compliance of the Center for Drug Evaluation and Research, leading enforcement and policy making for compliance with all drug requirements, including drug approval; current good manufacturing practices (GMP); human subject protection and bioresearch monitoring (GCP); import and export; and recalls. Before joining FDA, Ms. Autor was a Trial Attorney in the Office of Consumer Litigation of the U.S. Department of Justice, where she litigated civil and criminal cases on behalf of FDA. Skills and Qualifications: General Management Biosciences, Pharmaceuticals Regulatory Compliance Legal